If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What if a Trulicity® (dulaglutide) dose is missed?
If a dose of dulaglutide is missed and there are at least 3 days (72 hours) until the next scheduled dose, it should be administered as soon as possible.
See important safety information, including boxed warning, in the attached prescribing information.
Missed Dose
Dulaglutide is a human glucagon-like peptide-1 receptor agonist for once-weekly administration.1
If a dulaglutide dose is missed, the next dose depends on how much time there is before the patient's next regularly scheduled injection day ().1
If a dose of dulaglutide is missed and there are… |
Then… |
And... |
at least 72 hours until the next scheduled dose |
it should be administered as soon as possible |
patients can resume their regular once-weekly dosing schedule. |
less than 72 hours remaining before the next scheduled dose |
the missed dose should be skipped; the next dose should be administered on the regularly scheduled day |
The day of weekly administration can be changed, if necessary, as long as the last dulaglutide dose was administered 3 or more days before.1
Pharmacokinetics
Improvement in glycemic control can be observed after the first dulaglutide dose and is sustained throughout the once-weekly dosing interval.1,2
Steady-state plasma concentrations are achieved between 2 and 4 weeks following once-weekly administration.1
Once steady state is achieved, missing 2 or more consecutive doses may result in subtherapeutic dulaglutide concentrations ().3
Enclosed Prescribing Information
References
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625-634. http://dx.doi.org/10.1007/s40262-015-0338-3
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: June 02, 2022